This body of work gives a concise and comprehensive overview for the clinician and scientist on the latest treatment modalities for hypertrophic scars (HTS) and keloids in the pediatric population, as well as the most promising methods of prevention currently being investigated. This review will serve as a guide to the clinician for treatment selection and as an efficient tool for the scientist to achieve a comprehensive overview of the scientific literature to guide their future experiments aimed at pathologic scar prevention.
Recent Advances:
Current studies in the literature suggest carbon dioxide (CO2) laser and E-light (bipolar radiofrequency, intense pulsed light, and cooling) are two of the most effective treatment modalities for HTS, while surgical excision+CO2 laser+triamcinolone injection was one of the most successful treatments for keloids. In animal models, drug impregnated electrospun nanofiber dressings offer encouraging results for HTS prevention, while Kelulut honey showed promising results for keloid prevention.
Critical Issues:
Treatment outcome reproducibility is hindered by small cohorts of patients, inadequate-follow up, and variability in assessment tools. Prevention studies show multiple ways of achieving the same result, yet fall short of complete prevention. Furthermore, some studies that have purported full prevention have not been validated.
Future Directions:
To establish a standard of care, large clinical trials of the most successful modalities in small cohorts are needed. The key for prevention will be validation in animal models of the most successful methods, followed by translational and clinical studies.
Get full access to this article
View all access options for this article.
References
1.
HanasonoMM, KitaM, MikulecAA, LonerganD, KochRJ. Autocrine growth factor production by fetal, keloid, and normal dermal fibroblasts. Arch Facial Plast Surg, 2003; 5:26–30.
2.
LuoS, BenathanM, RaffoulW, PanizzonRG, EgloffDV. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast Reconstr Surg, 2001; 107:87–96.
3.
ChinGS, LiuW, SteinbrechD, HsuM, LevinsonH, LongakerMT. Cellular signaling by tyrosine phosphorylation in keloid and normal human dermal fibroblasts. Plast Reconstr Surg, 2000; 106:1532–1540.
4.
XinY, WangX, ZhuM, et al.Expansion of CD26 positive fibroblast population promotes keloid progression. Exp Cell Res, 2017; 356:104–113.
5.
LeeDH, JinCL, KimY, et al.Pleiotrophin is downregulated in human keloids. Arch Dermatol Res, 2016; 308:585–591.
6.
De FeliceB, CiarmielloLF, MondolaP, et al.Differential p63 and p53 expression in human keloid fibroblasts and hypertrophic scar fibroblasts. DNA Cell Biol, 2007; 26:541–547.
7.
HuZC, TangB, GuoD, et al.Expression of insulin-like growth factor-1 receptor in keloid and hypertrophic scar. Clin Exp Dermatol, 2014; 39:822–828.
8.
LeeJH, ShinJU, JungI, et al.Proteomic profiling reveals upregulated protein expression of hsp70 in keloids. Biomed Res Int, 2013; 2013:621538.
9.
LiC, BaiY, LiuH, et al.Comparative study of microRNA profiling in keloid fibroblast and annotation of differential expressed microRNAs. Acta Biochim Biophys Sin (Shanghai), 2013; 45:692–699.
10.
UchidaG, YoshimuraK, KitanoY, OkazakiM, HariiK. Tretinoin reverses upregulation of matrix metalloproteinase-13 in human keloid-derived fibroblasts. Exp Dermatol, 2003; 12(Suppl 2):35–42.
11.
LeeTY, ChinGS, KimWJ, ChauD, GittesGK, LongakerMT. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg, 1999; 43:179–184.
12.
MessadiDV, BertolamiCN. CD44 and hyaluronan expression in human cutaneous scar fibroblasts. Am J Pathol, 1993; 142:1041–1049.
13.
WassermannRJ, PoloM, SmithP, WangX, KoF, RobsonMC. Differential production of apoptosis-modulating proteins in patients with hypertrophic burn scar. J Surg Res, 1998; 75:74–80.
14.
ScottPG, DoddCM, GhaharyA, ShenYJ, TredgetEE. Fibroblasts from post-burn hypertrophic scar tissue synthesize less decorin than normal dermal fibroblasts. Clin Sci (Lond), 1998; 94:541–547.
15.
GhaharyA, ShenYJ, NedelecB, WangR, ScottPG, TredgetEE. Collagenase production is lower in post-burn hypertrophic scar fibroblasts than in normal fibroblasts and is reduced by insulin-like growth factor-1. J Invest Dermatol, 1996; 106:476–481.
16.
ZuoJ, ChenZ, ZhongX, LanW, KuangY, HuangD. FBP1 is highly expressed in human hypertrophic scars and increases fibroblast proliferation, apoptosis, and collagen expression. Connect Tissue Res, 2018; 59:120–128.
17.
ZhangZ, FinnertyCC, HeJ, HerndonDN. Smad ubiquitination regulatory factor 2 expression is enhanced in hypertrophic scar fibroblasts from burned children. Burns, 2012; 38:236–246.
18.
XieJL, QiSH, PanS, et al.Expression of Smad protein by normal skin fibroblasts and hypertrophic scar fibroblasts in response to transforming growth factor beta1. Dermatol Surg, 2008; 34:1216–1224; discussion 1224–1225.
19.
ZhouLJ, OnoI, KanekoF. Role of transforming growth factor-beta 1 in fibroblasts derived from normal and hypertrophic scarred skin. Arch Dermatol Res, 1997; 289:646–652.
20.
BockO, YuH, ZitronS, BayatA, FergusonMW, MrowietzU. Studies of transforming growth factors beta 1–3 and their receptors I and II in fibroblast of keloids and hypertrophic scars. Acta Derm Venereol, 2005; 85:216–220.
21.
OgawaR. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci, 2017; 18:606.
22.
GhazawiFM, ZarghamR, GilardinoMS, SassevilleD, JafarianF. Insights into the pathophysiology of hypertrophic scars and keloids: how do they differ?. Adv Skin Wound Care, 2018; 31:582–595.
23.
KrakowskiAC, TotriCR, DonelanMB, ShumakerPR. Scar management in the pediatric and adolescent populations. Pediatrics, 2016; 137:e20142065.
24.
ŻądkowskiT, NachulewiczP, MazgajM, et al.A new CO2 laser technique for the treatment of pediatric hypertrophic burn scars: an observational study. Medicine (Baltimore), 2016; 95:e5168.
25.
AcostaS, UretaE, YañezR, OlivaN, SearleS, GuerraC. Effectiveness of intralesional triamcinolone in the treatment of keloids in children. Pediatr Dermatol, 2016; 33:75–79.
26.
AlsharnoubiJ, ShoukryKE, FawzyMW, MohamedO. Evaluation of scars in children after treatment with low-level laser. Lasers Med Sci, 2018; 33:1991–1995.
27.
Armendariz-BorundaJ, Lyra-GonzalezI, Medina-PreciadoD, et al.A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg, 2012; 68:22–28.
28.
ElmelegyNG, HegazyAM, SadakaMS, AbdeldaimDE. Electrophotobiomodulation in the treatment of facial post-burn hypertrophic scars in pediatric patients. Ann Burns Fire Disasters, 2018; 31:127–132.
29.
MajidI, ImranS. Fractional carbon dioxide laser resurfacing in combination with potent topical corticosteroids for hypertrophic burn scars in the pediatric age group: an open label study. Dermatol Surg, 2018; 44:1102–1108.
30.
PatelSP, NguyenHV, MannschreckD, RedettRJ, PuttgenKB, StewartFD. Fractional CO2 laser treatment outcomes for pediatric hypertrophic burn scars. J Burn Care Res, 2019; 40:386–391.
31.
WeiY, Li-TsangCWP, LiuJ, XieL, YueS. 3D-printed transparent facemasks in the treatment of facial hypertrophic scars of young children with burns. Burns, 2017; 43:e19–e26.
32.
HerndonD, CapekKD, RossE, et al.Reduced postburn hypertrophic scarring and improved physical recovery with yearlong administration of oxandrolone and propranolol. Ann Surg, 2018; 268:431–441.
33.
ArtziO, KorenA, NivR, MehrabiJN, FriedmanO. The scar bane, without the pain: a new approach in the treatment of elevated scars: thermomechanical delivery of topical triamcinolone acetonide and 5-fluorouracil. Dermatol Ther (Heidelb), 2019; 9:321–326.
34.
ArtziO, KorenA, NivR, MehrabiJN, MashiahJ, FriedmanO. A new approach in the treatment of pediatric hypertrophic burn scars: tixel-associated topical triamcinolone acetonide and 5-fluorouracil delivery. J Cosmet Dermatol, 2020; 19:131–134.
35.
BonnardeauxE, McCuaigC. Surgical excision combined with fully ablative carbon dioxide laser therapy and triamcinolone injections as a potential treatment for keloids in children. Pediatr Dermatol, 2020; 37:137–141.
36.
ElrodJ, SchiestlC, NeuhausD, MohrC, NeuhausK. Patient- and physician-reported outcome of combined fractional CO2 and pulse dye laser treatment for hypertrophic scars in children. Ann Plast Surg, 2020; 85:237–244.
37.
ParkTH, ChangCH. Location of keloids and its treatment modality may influence the keloid recurrence in children. J Craniofac Surg, 2015; 26:1355–1357.
38.
ZuccaroJ, MuserI, SinghM, YuJ, KellyC, FishJ. Laser therapy for pediatric burn scars: focusing on a combined treatment approach. J Burn Care Res, 2018; 39:457–462.
39.
GauglitzGG, KortingHC, PavicicT, RuzickaT, JeschkeMG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med, 2011; 17:113–125.
40.
JiangZ, ZhaoL, HeF, et al.Palmatine-loaded electrospun poly(ɛ-caprolactone)/gelatin nanofibrous scaffolds accelerate wound healing and inhibit hypertrophic scar formation in a rabbit ear model. J Biomater Appl, 2021; 35:869–886.
41.
SunX, ChengL, ZhuW, et al.Use of ginsenoside Rg3-loaded electrospun PLGA fibrous membranes as wound cover induces healing and inhibits hypertrophic scar formation of the skin. Colloids Surf B Biointerfaces, 2014; 115:61–70.
42.
CuiW, ChengL, HuC, LiH, ZhangY, ChangJ. Electrospun poly(L-lactide) fiber with ginsenoside rg3 for inhibiting scar hyperplasia of skin. PLoS One, 2013; 8:e68771.
43.
ZhangN, GaoT, WangY, et al.Modulating cationicity of chitosan hydrogel to prevent hypertrophic scar formation during wound healing. Int J Biol Macromol, 2020; 154:835–843.
44.
LiY, ShiS, GaoJ, et al.Cryptotanshinone downregulates the profibrotic activities of hypertrophic scar fibroblasts and accelerates wound healing: a potential therapy for the reduction of skin scarring. Biomed Pharmacother, 2016; 80:80–86.
45.
NabaiL, KilaniRT, AminuddinF, LiY, GhaharyA. Methotrexate modulates the expression of MMP-1 and type 1 collagen in dermal fibroblast. Mol Cell Biochem, 2015; 409:213–224.
46.
CameronAM, TurnerCT, AdamsDH, et al.Flightless I is a key regulator of the fibroproliferative process in hypertrophic scarring and a target for a novel antiscarring therapy. Br J Dermatol, 2016; 174:786–794.
47.
ZhaoD, WangY, DuC, et al.Honokiol alleviates hypertrophic scar by targeting transforming growth factor-β/Smad2/3 signaling pathway. Front Pharmacol, 2017; 8:206.
48.
BaiX, HeT, LiuJ, et al.Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-β/Smad pathway. Exp Dermatol, 2015; 24:355–360.
49.
HouQ, HeWJ, HaoHJ, et al.The four-herb Chinese medicine ANBP enhances wound healing and inhibits scar formation via bidirectional regulation of transformation growth factor pathway. PLoS One, 2014; 9:e112274.
50.
LiP, LiuP, XiongRP, et al.Ski, a modulator of wound healing and scar formation in the rat skin and rabbit ear. J Pathol, 2011; 223:659–671.
51.
ZhongL, HaoH, ChenD, et al.Arsenic trioxide inhibits the differentiation of fibroblasts to myofibroblasts through nuclear factor erythroid 2-like 2 (NFE2L2) protein and the Smad2/3 pathway. J Cell Physiol, 2019; 234:2606–2617.
52.
ShiJ, WuY, GuoS, ZhangH, ChenG, XuX. The efficacy of anti-VEGF antibody-modified liposomes loaded with paeonol in the prevention and treatment of hypertrophic scars. Drug Dev Ind Pharm, 2019; 45:439–455.
ZhouN, LiD, LuoY, LiJ, WangY. Effects of botulinum toxin type A on microvessels in hypertrophic scar models on rabbit ears. Biomed Res Int, 2020; 2020:2170750.
55.
MaL, LiLY, ZhaoTL. Anti-inflammatory effects of ginsenoside Rg3 on the hypertrophic scar formation via the NF-κB/IκB signaling pathway in rabbit ears. Pharmazie, 2020; 75:102–106.
LiuXJ, XuMJ, FanST, et al.Xiamenmycin attenuates hypertrophic scars by suppressing local inflammation and the effects of mechanical stress. J Invest Dermatol, 2013; 133:1351–1360.
58.
SunX, PhanTN, JungSH, et al.LCB 03–0110, a novel pan-discoidin domain receptor/c-Src family tyrosine kinase inhibitor, suppresses scar formation by inhibiting fibroblast and macrophage activation. J Pharmacol Exp Ther, 2012; 340:510–519.
59.
Rahmani-NeishaboorEP, YauFM-kMD, JaliliRP, KilaniRTP, GhaharyAP. Improvement of hypertrophic scarring by using topical anti-fibrogenic/anti-inflammatory factors in a rabbit ear model. Wound Repair Regen, 2010; 18:401–408.
60.
WongVW, RustadKC, AkaishiS, et al.Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. Nat Med, 2011; 18:148–152.
61.
ZhuYZ, HuX, ZhangJ, WangZH, WuS, YiYY. Extracellular vesicles derived from human adipose-derived stem cell prevent the formation of hypertrophic scar in a rabbit model. Ann Plast Surg, 2020; 84:602–607.
62.
LiuS, JiangL, LiH, et al.Mesenchymal stem cells prevent hypertrophic scar formation via inflammatory regulation when undergoing apoptosis. J Invest Dermatol, 2014; 134:2648–2657.
63.
NordinA, ChowdhurySR, SaimAB, Bt Hj IdrusR. Effect of Kelulut honey on the cellular dynamics of TGFβ-induced epithelial to mesenchymal transition in primary human keratinocytes. Int J Environ Res Public Health, 2020; 17:3229.
64.
MurphyA, LeVatteT, BoudreauC, et al.Angiotensin II type I receptor blockade is associated with decreased cutaneous scar formation in a rat model. Plast Reconstr Surg, 2019; 144:803e–813e.
65.
Gallant-BehmCL, PiperJ, LynchJM, et al.A microRNA-29 mimic (remlarsen) represses extracellular matrix expression and fibroplasia in the skin. J Invest Dermatol, 2019; 139:1073–1081.
66.
RenJ, LiuS, WanJ, KangE, ChenZ. Effect of hyperbaric oxygen on the process of hypertrophic scar formation in rabbit ears. J Cosmet Dermatol, 2018; 17:1240–1249.
67.
Fernández-MayolaM, BetancourtL, Molina-KautzmanA, et al.Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. Int Wound J, 2018; 15:538–546.
GisquetH, LiuH, BlondelWC, et al.Intradermal tacrolimus prevent scar hypertrophy in a rabbit ear model: a clinical, histological and spectroscopical analysis. Skin Res Technol, 2011; 17:160–166.
70.
UzunHMD, BitikOMD, HekimogluRMD, AtillaPMD, KaykcogluAUMD. Angiotensin-converting enzyme inhibitor enalapril reduces formation of hypertrophic scars in a rabbit ear wounding model. Plast Reconstr Surg, 2013; 132:361e–371e.
WilgusTA. Vascular endothelial growth factor and cutaneous scarring. Adv Wound Care (New Rochelle), 2019; 8:671–678.
73.
DiPietroLA. Angiogenesis and wound repair: when enough is enough. J Leukoc Biol, 2016; 100:979–984.
74.
MaK, KwonSH, PadmanabhanJ, et al.Controlled delivery of a focal adhesion kinase inhibitor results in accelerated wound closure with decreased scar formation. J Invest Dermatol, 2018; 138:2452–2460.
75.
HahnJM, GlaserK, McFarlandKL, AronowBJ, BoyceST, SuppDM. Keloid-derived keratinocytes exhibit an abnormal gene expression profile consistent with a distinct causal role in keloid pathology. Wound Repair Regen, 2013; 21:530–544.
76.
VinaikR, BarayanD, AugerC, AbdullahiA, JeschkeMG. Regulation of glycolysis and the Warburg effect in wound healing. JCI Insight, 2020; 5e138949.
77.
MaD, ChenL, ShiJ, et al.Pigment epithelium-derived factor attenuates angiogenesis and collagen deposition in hypertrophic scars. Wound Repair Regen, 2020; 28:684–695.
78.
HeT, ZhangY, LiuY, et al.MicroRNA-494 targets PTEN and suppresses PI3K/AKT pathway to alleviate hypertrophic scar formation. J Mol Histol, 2019; 50:315–323.
79.
LabergeA, MerjanehM, ArifS, LarochelleS, MoulinVJ. Shedding of proangiogenic microvesicles from hypertrophic scar myofibroblasts. Exp Dermatol, 2021; 30:112–120.
80.
LiuJ, ZhaoB, ZhuH, et al.Wnt4 negatively regulates the TGF-β1-induced human dermal fibroblast-to-myofibroblast transition via targeting Smad3 and ERK. Cell Tissue Res, 2020; 379:537–548.
81.
CarneyBC, ChenJH, KentRA, et al.Reactive oxygen species scavenging potential contributes to hypertrophic scar formation. J Surg Res, 2019; 244:312–323.
82.
XuZ, GuoB, ChangP, HuiQ, LiW, TaoK. The differential expression of miRNAs and a preliminary study on the mechanism of miR-194-3p in keloids. Biomed Res Int, 2019; 2019:8214923.
83.
HoerstK, van den BroekL, SachseC, et al.Regenerative potential of adipocytes in hypertrophic scars is mediated by myofibroblast reprogramming. J Mol Med (Berl), 2019; 97:761–775.
84.
MedinaJL, SebastianEA, FourcaudotAB, DoratiR, LeungKP. Pirfenidone ointment modulates the burn wound bed in C57BL/6 mice by suppressing inflammatory responses. Inflammation, 2019; 42:45–53.
85.
ZhangL, QinH, WuZ, ChenW, ZhangG. Identification of the potential targets for keloid and hypertrophic scar prevention. J Dermatolog Treat, 2018; 29:600–605.
86.
HuZC, ShiF, LiuP, et al.TIEG1 represses Smad7-mediated activation of TGF-β1/Smad signaling in keloid pathogenesis. J Invest Dermatol, 2017; 137:1051–1059.
87.
AnG, LiangS, ShengC, LiuY, YaoW. Upregulation of microRNA-205 suppresses vascular endothelial growth factor expression-mediated PI3K/Akt signaling transduction in human keloid fibroblasts. Exp Biol Med (Maywood), 2017; 242:275–285.
88.
ZhuZ, DingJ, MaZ, IwashinaT, TredgetEE. Systemic depletion of macrophages in the subacute phase of wound healing reduces hypertrophic scar formation. Wound Repair Regen, 2016; 24:644–656.
89.
GrasC, RatusznyD, HadamitzkyC, ZhangH, BlasczykR, FigueiredoC. miR-145 contributes to hypertrophic scarring of the skin by inducing myofibroblast activity. Mol Med, 2015; 21:296–304.
90.
GauglitzGG, BureikD, ZwickerS, RuzickaT, WolfR. The antimicrobial peptides psoriasin (S100A7) and koebnerisin (S100A15) suppress extracellular matrix production and proliferation of human fibroblasts. Skin Pharmacol Physiol, 2015; 28:115–123.
91.
HataS, OkamuraK, HattaM, IshikawaH, YamazakiJ. Proteolytic and non-proteolytic activation of keratinocyte-derived latent TGF-β1 induces fibroblast differentiation in a wound-healing model using rat skin. J Pharmacol Sci, 2014; 124:230–243.
92.
FoleyTT, EhrlichHP. Through gap junction communications, co-cultured mast cells and fibroblasts generate fibroblast activities allied with hypertrophic scarring. Plast Reconstr Surg, 2013; 131:1036–1044.
93.
ChoJW, IlKJ, LeeKS. Downregulation of type I collagen expression in silibinin-treated human skin fibroblasts by blocking the activation of Smad2/3-dependent signaling pathways: potential therapeutic use in the chemoprevention of keloids. Int J Mol Med, 2013; 31:1148–1152.
94.
HuX, RanH, DechangW, YibingW, YongqiangF, QiangL. Absence of the adenosine A(2A) receptor attenuates hypertrophic scarring in mice. J Burn Care Res, 2013; 34:e161–e167.
95.
Chavez-MuñozC, HartwellR, JaliliRB, et al.SPARC/SFN interaction, suppresses type I collagen in dermal fibroblasts. J Cell Biochem, 2012; 113:2622–2632.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
